0001144204-11-047242.txt : 20110815 0001144204-11-047242.hdr.sgml : 20110815 20110815162006 ACCESSION NUMBER: 0001144204-11-047242 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110815 DATE AS OF CHANGE: 20110815 EFFECTIVENESS DATE: 20110815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 111036614 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v232084_13f-hr.txt FORM 13F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: June 30, 2011 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. May 16, 2011 -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 50 ----------- Form 13F Information Table Entry Value: $2,608,928 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 6-30-11
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- ----- ------- ------- --- ---- ---------- -------- ---- ------ ---- 1 Acadia Pharmaceuticals Inc. COM 004225108 7,114 4,364,420 SH SOLE 4,364,420 2 Adolor Corp. COM 00724X102 13,825 6,947,343 SH SOLE 6,947,343 3 Aegerion Pharmaceuticals Inc. COM 00767E102 613 38,905 SH SOLE 38,905 4 Alere Inc. PFD Conv PFD CONV 01449J204 207 742 SH SOLE 742 5 Alkermes COM 01642T108 2,139 115,000 SH SOLE 115,000 6 Amicus Therapeutics COM 03152W109 6,532 1,099,675 SH SOLE 1,099,675 7 Anacor Pharmaceuticals COM 32420101 3,998 618,897 SH SOLE 618,897 8 Anthera Pharmaceuticals COM 03674U102 7,353 900,000 SH SOLE 900,000 9 AP Pharma COM 00202J203 1,647 6,861,818 SH SOLE 6,861,818 10 Aradigm Corp. COM 038505301 19 100,000 SH SOLE 100,000 11 Ardea Biosciences Inc. COM 03969P107 153,064 6,011,989 SH SOLE 6,011,989 12 Ariad Pharmaceuticals Inc. COM 04033A100 8,896 785,160 SH SOLE 785,160 13 Auxilium COM 05334D107 142,917 7,291,708 SH SOLE 7,291,708 14 Avanir Pharmaceuticals COM 05348P401 1,680 500,000 SH SOLE 500,000 15 Biocryst Pharmaceuticals Inc. COM 09058V103 21,253 5,563,615 SH SOLE 5,563,615 16 BioDelivery Sciences Intl. Inc. COM 09060J106 7,764 2,403,848 SH SOLE 2,403,848 17 Biomarin COM 09061G101 7,585 278,758 SH SOLE 278,758 18 Chelsea Therapeutics COM 163428105 5,685 1,114,700 SH SOLE 1,114,700 19 Cyclacel Pharmaceuticals PFD Pfd. Conv. Ex 6% CONV EX 23254L207 84 20,979 SH SOLE 20,979 20 Cumberland Pharmaceuticals COM 230770109 554 96,381 SH SOLE 96,381 21 Exelixis Inc. COM 30161Q104 14,281 1,593,810 SH SOLE 1,593,810 22 Genomic Health Inc. COM 37244C101 219,465 7,863,337 SH SOLE 7,863,337 23 GTX Inc. COM 40052B108 10,195 2,128,406 SH SOLE 2,128,406 24 Halozyme Therapeutics Inc. COM 40637H109 26,511 3,836,683 SH SOLE 3,836,683 25 Idenix Pharmaceuticals Inc. COM 45166R204 2,863 572,576 SH SOLE 572,576 26 Idera Pharmaceuticals Inc. COM 45168K108 620 288,401 SH SOLE 288,401 27 Incyte Corp. COM 45337C102 209,866 11,080,561 SH SOLE 11,080,561 28 Inhibitex Inc. COM 45719T103 3,062 781,249 SH SOLE 781,249 29 Intermune Inc. COM 45884X103 18,256 509,232 SH SOLE 509,232 30 Ligand Pharmaceuticals Inc. CLASS B 53220K207 877 73,401 SH SOLE 73,401 31 Medivation Inc. COM 58501N101 11,380 531,018 SH SOLE 531,018 32 Micromet COM 59509C105 12,293 2,141,556 SH SOLE 2,141,556 33 Pharmacyclics Inc. COM 716933106 59,638 5,712,447 SH SOLE 5,712,447 34 Pharmasset Inc. COM 71715N106 225,824 2,012,691 SH SOLE 2,012,691 35 Salix Pharmaceuticals, Inc. COM 795435106 2,638 66,241 SH SOLE 66,241 36 Seattle Genetics Inc. COM 812578102 395,691 19,283,142 SH SOLE 19,283,142 37 Threshold Pharma COM 885807107 6,125 3,667,644 SH SOLE 3,667,644 38 Tranzyme COM 89413J102 5,643 1,350,000 SH SOLE 1,350,000 39 Trimeris Inc. COM 896263100 8,585 3,475,475 SH SOLE 3,475,475 40 Via Pharmaceuticals COM 92554T103 5 102,881 SH SOLE 102,881 41 Viropharma Inc. COM 928241108 179,226 9,687,889 SH SOLE 9,687,889 42 Xoma Ltd. COM G9825R206 941 400,400 SH SOLE 400,400 43 YM Biosciences COM 984238105 25,602 9,078,803 SH SOLE 9,078,803 44 Ziopharm Oncology Inc. COM 98973P101 5,199 849,500 SH SOLE 849,500 45 Alere Inc. Conv. CONV Notes 3% 5/15/16 BONDS 01449JAA3 6,513 5,982,000 PRN SOLE 5,982,000 46 Biomarin Pharmaceuticals CONV Notes 1.875% 4/23/2017 BONDS 09061GAD3 9,213 6,398,000 PRN SOLE 6,398,000 47 Incyte Genomics CONV Notes 4.75% 10/1/2015 BONDS 45337CAH5 368,800 160,000,000 PRN SOLE 160,000,000 48 Intermune Inc CONV Notes 5% 3/1/15 BONDS 45884XAD5 42,603 20,801,000 PRN SOLE 20,801,000 49 Salix 144A CONV 5.5% 8/15/28 BONDS 795435AB2 194,124 44,500,000 PRN SOLE 44,500,000 50 Salix 2.75% CONV 5/15/15 BONDS 795435AC0 149,960 130,400,000 PRN SOLE 130,400,000 --------- 2,608,928 =========
Report Type |X| 13F Holdings Report List of Other Managers NONE Report Summary Number of other Included Managers 0 Form 13F Information Table Entry Total 50 Form 13F Information Table Entry Value 2,608,928